<DOC>
	<DOCNO>NCT00820690</DOCNO>
	<brief_summary>The purpose study analyze gene expression signature immunohistochemical marker associate clinical pathological response neoadjuvant chemotherapy locally advance breast cancer .</brief_summary>
	<brief_title>Neoadjuvant Chemotherapy Locally Advanced Breast Cancer</brief_title>
	<detailed_description>Locally advanced breast cancer common condition development country . Neoadjuvant chemotherapy give opportunity identify genetic signature associate objective clinical pathological complete response . Patients receive doxorubicin/cyclophosphamide paclitaxel . Tumor sample collect chemotherapy analyze .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Women locally advance woman breast cancer Histology : ductal ou lobular invasive histology Agreement take part study signature inform consent Clinical condition receive doxorubicin/cyclophosphamide paclitaxel ECOG 0 I Not clinical stage III Inflammatory breast cancer Previous treatment Previous diagnosis cancer ( except basal cell squamous cell skin carcinoma noninvasive cervical carcinoma ) Pregnancy Absence clinical condition receive chemotherapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>neoadjuvant chemotherapy</keyword>
	<keyword>advanced breast cancer</keyword>
	<keyword>microarray</keyword>
	<keyword>correlation analysis</keyword>
	<keyword>oncoplastic surgery</keyword>
</DOC>